controlled trials of BTX-A for chronic migraines. Differences were settled via consensus. Data extraction/verification were managed similarly. The primary outcome was baseline-endpoint change in migraine frequency (number/month). Heterogeneity was assessed using $\chi^2$ and I-squared. Two raters assessed study quality using the Downs-Black scale, with adjudication via consensus. A fixed-effects model combined study results using the standardized mean difference (Cohen’s d) in monthly migraine frequency between placebo and BTX-A groups. RESULTS: Nine trials ($N = 2114$; BTX-A = 1388, placebo = 726; 2059 completed their trials) provided data in 19 study arms and 9 placebo arms. The average age was 43 $\pm$ 3, duration of illness was 20 $\pm$ 3 years, average number of migraines was 6.0 $\pm$ 2.1/month, 84% were females. All $\chi^2$ were non-significant; all I-squared were 0, suggesting combinability and confirmed using a fixed-effects model. Quality scores averaged 67% $\pm$ 4% ("fair"; range: 62%–75%). The weighted average treatment effect (Cohen’s d) of BTX-A over placebo was $-0.05$ (CI95% = $-0.13$, 0.03) when measured 30 days after injection, $-0.04$ (CI95% = $-0.12$, 0.04) at 60 days, and $-0.04$ (CI95% = $-0.12$, 0.04) at 90 days post-injection. Two comparisons out of 57 were significant; one by Relja after 60 days and one by Vo after 90 days. Controlling for placebo effect and stratifying by dose stratification found no significant effect of BTX-A in reducing migraine frequency per month over saline vehicle. CONCLUSION: BTX-A used as prophylactic treatment of chronic migraine headaches does not decrease monthly numbers of migraines.

THE BALANCE BETWEEN SEVERE CARDIOVASCULAR AND GASTROINTESTINAL EVENTS AMONG USERS OF SELECTIVE AND NON-SELECTIVE NON STEROIDAL ANTI-INFLAMMATORY DRUGS
Van der Linden MW$, Van der Bij S$, Welsing P$, Kuipers E$, Herings RM$

1PHARMO Institute for Drug Outcomes Research, Utrecht, Netherlands, 2PHARMO Institute, Utrecht, Utrecht, Netherlands, 3Pfizer BV, Capelle a/d Ijssel, ZH, Netherlands, 4Erasmus Medical Center, Rotterdam, Netherlands, 5PHARMO Institute, Utrecht, Netherlands

OBJECTIVE: To simultaneously assess risk of acute myocardial infarction (AMI), any cardiovascular (CV) and gastrointestinal (GI) events with traditional non-selective NSAIDs (tNSAIDs) and COX-2-inhibitors (coxibs). METHODS: Using the PHARMO Record Linkage System, including drug-dispensing and hospitalization data of >2 million residents of The Netherlands, subjects with a first hospitalization for AMI or CV diagnoses were identified. NSAID and coxib use was classified into remote, recent and current use. Naphrofen users were excluded. Cases were matched to controls in a 1 to 4 ratio on age and date. Multivariate analyses adjusted for gender, history of hospitalizations and medications. RESULTS: Compared with remote use, AMI risk was increased among current users of coxibs combined (adjusted OR 1.63, 95% confidence interval 1.24–2.16) and among current users of tNSAIDs combined (adjusted OR 1.29, 95% CI 1.08–1.55). AMI risk with current use of celecoxib (1.63, 1.09-3.45), rofecoxib (1.59, 1.15-2.19), ibuprofen (1.54, 1.13-2.09) and diclofenac (1.43, 1.13-1.82) was significantly increased. Risk of any CV event with current use of celecoxib, rofecoxib, diclofenac and tNSAIDs other than ibuprofen or diclofenac was significantly increased (adjusted OR ranged from 1.22 to 1.70). GI risk with current use of rofecoxib (1.73, 1.27–2.35), ibuprofen (1.40, 1.00–1.85), diclofenac (4.40, 3.55–5.44) and other tNSAIDs (2.38, 1.86–3.04), but not celecoxib (1.06, 0.47–2.35) was significantly increased. Compared with current use of celecoxib, adjusted AMI and CV risk was not significantly increased with current use of individual coxibs and individual tNSAIDs, but GI risk was increased with diclofenac (adjusted OR 4.17, 95% CI. 1.83–9.51). CONCLUSION: AMI and CV risk was similarly increased with individual coxibs and tNSAIDs. Use of diclofenac strongly increased GI risk. Residual confounding and “channelling” can not be excluded.

OBJECTIVE: To provide cross-cultural comparisons of health and behavior in obese individuals. METHODS: We analyzed data from the 2006 National Health and Wellness Survey, a cross-sectional Internet-based survey conducted annually in the United States and Europe (FR, DE, UK, SP and IT). When weighted, the sample is representative of the country’s adult population in terms of key sociodemographic characteristics. The survey gathers information regarding demographics, health conditions, quality of life, and health care use. Adults were classified as overweight/obese (OWOB) based on BMI $\geq 25$. Comparisons between groups were conducted using the Chi-square test with a significance level of $p < 0.05$. RESULTS: Almost 70% (144 M) of the United States population is OWOB, compared to just over half of Europeans (131 M). In both regions the OWOB populations were typically married and employed, with a mean age of 48 yrs (USA) and 51 yrs (EU) ($p < 0.05$). Both had high rates of cardiovascular co-morbidities and a family history of obesity or diabetes. The majority reported having less than very good health and “some/little/no” energy in the past four weeks. Most had seen a health care provider in the past six months (82% USA vs. 87% EU; $p < 0.05$). Although many claimed to be taking steps to lose weight (62% US vs. 50% EU; $p < 0.05$), most reported weight gain over the past 6 months (30% US vs. 28% EU; $p < 0.05$). Only a small portion reported taking a weight-loss prescription (1.9% US vs. 3.5% EU; $p < 0.05$); but most of the remainder would consider taking one (45% US vs. 36% EU; $p < 0.05$). CONCLUSION: The obesity problem is more evident in the United States. Americans exhibit higher rates of obesity at a younger age but have fewer provider visits and use of prescriptons, suggesting potential solutions to the problem.

THE PREVALENCE OF PAIN SYMPTOMS AMONG UNITED STATES ADULTS AGED 65 AND OLDER
McDonald M$, Hertz RP$, Unger AN$, Lustik MB$

1Pfizer Inc, New York, NY, USA, 2Science Applications International Corporation, Reston, VA, USA

OBJECTIVE: Pain symptoms are common among adults aged 65 and older, but prevalence rates have not been updated to reflect current national data. We assess prevalence among U.S. adults aged 65 and older with respect to pain (joint, lower back, neck, severe headaches or migraines) and describe symptoms by gender, obesity, and arthritis status. METHODS: Analysis of nationally representative data collected from adults aged 65 and older ($n = 3810$) participating in the National Health and Nutrition Examination Survey (NHANES) 1999–2004. RESULTS: Joint pain and lower back pain are the most frequently reported type of pain, affecting 55% and 38% of elders, respectively. Women are significantly more likely than men...
to report joint pain, 59% vs. 49%, lower back pain, 42% vs. 33%, and severe headaches, 12% vs. 6% (p < 0.0001 for all pain differences). Knee joint pain is significantly higher in women than men (34% vs. 26%), as is finger joint pain (24% vs. 16%). Obese older adults have a higher prevalence than non-obese elders of knee pain (41% vs. 26%) and shoulder pain (21% vs. 16%). Elders with arthritis are about three times more likely than elders without arthritis to have joint pain of the knee (45% vs. 14%), finger (32% vs. 9%), shoulder (26% vs. 8%), and ankle (20% vs. 8%). CONCLUSION: Pain symptoms are highly prevalent among older adults, particularly older women. Joint pain disproportionately affects obese and arthritic older adults. These findings call for increased recognition among providers and targeted interventions promoting symptom management and weight reduction.

PSY7

BURDEN OF OBESITY: 10-YEAR REVIEW OF PUBLISHED LITERATURE ON OBESITY PREVALENCE IN NINE COUNTRIES
Barrett AM1, Boye K2, Oyelowo O2
1RTI Health Solutions, RTP, NC, USA, 2Eli Lilly and Company, Indianapolis, IN, USA

OBJECTIVE: To examine data published over the past ten years describing measured and self-reported obesity prevalence among adults in Australia, Canada, France, Germany, Italy, Spain, Sweden, the UK, and the US. METHODS: A review of the medical literature published from 1997 to 2007 was conducted, including MEDLINE, EMBASE, Current Contents Connect, and International Pharmaceutical Abstracts databases; ISPOR abstracts; and data published on the Internet by WHO and relevant governmental agencies. RESULTS: Prevalence of obesity varies significantly based on the mode of measurement. Studies based on measured weight and height report prevalence 35% to 86%; higher than comparable studies based on self-reported weight and height. Obesity prevalence has increased significantly during the past two to three decades for most of the countries reviewed; prevalence in Italy, however, does not appear to have increased dramatically. Rates of increase in prevalence for most countries range from 40% to 60% over the past two decades. The US has the highest prevalence of obesity worldwide (approximately 32%). Australia, Canada, Germany, and the UK also have relatively high obesity prevalence (range: 18% to 23%). France, Italy, Spain, and Sweden have comparatively low obesity prevalence (range: 9% to 15%); however, rates of increase are similar to those of countries with higher obesity prevalence. CONCLUSION: Prevalence of obesity varies substantially among these countries. Given the rapid rate of increase in obesity prevalence and the variation between prevalence rates derived from measured and self-reported data, studies based on recently collected measured data are necessary to understand global obesity epidemiology.

PSY8

THE ECONOMIC BURDEN OF SYSTEMIC LUPUS ERYTHEMATOSUS AMONG PATIENTS OF THE CAROLINA LUPUS STUDY EARLY IN THE COURSE OF DISEASE
Campbell Jr R1, Cooper GS2, Gilkeson GS3
1Medical University of South Carolina, Charleston, SC, USA, 2US Environmental Protection Agency, Washington, DC, USA, 3Medical University of South Carolina/ Ralph Johnson Medical Center, Charleston, SC, USA

OBJECTIVE: Our primary objective was to quantify differences in direct and indirect costs (i.e., costs of health care utilization and costs associated with job loss, respectively), and identify predictors of total cost based upon data provided at the follow-up assessment. METHODS: The Carolina Lupus Study is a population-based case-control study of SLE conducted in eastern and central NC and SC. Controls were identified through driver’s license records and frequency matched to cases by age, sex, and state. The 2001 follow-up assessed health care utilization in the past 12 months. Health care utilization per-unit annual costs (converted to 2001 US dollars) of 198 SLE patients were compared to those of 298 controls. The natural logarithm was taken of health care services which were used in linear regression to predict factors associated with an increase or decrease in the magnitude of total annual cost for cases and controls. RESULTS: Annual mean direct costs for health care was $12,375 (sd $13,723) in cases compared with $3,718 (sd $6,135) in controls (p < 0.0001). The annual mean salary was $21,540 (sd 11215) among the 47 cases and $24,909 (sd 9399) among the nine controls who had stopped working due to health reasons. When averaged across the full follow-up sample (199 cases and 298 controls), the average annual cost of wages lost due to illness was $5,113 and $749 in cases and controls, respectively (p < 0.0001). Predictors of higher costs among cases were lower education level (less than high school), renal disease, and serositis. CONCLUSION: There are no published studies which compare medical expenditure costs of SLE patients to matched-controls. Health utilization costs were significantly different for nine out of the ten health services and indirect costs between cases and controls were considerable implicate a need for financial support amongst minorities and women, populations disproportionately affected by SLE.

PSY9

RISK FACTORS AND RISKS ASSOCIATED WITH HOSPITAL STAYS IN PATIENTS WITH MYALGIA
Justice EE, Cerrieto PB
University of Louisville, Louisville, KY, USA

OBJECTIVE: The risk factors for myalgia were examined along with other data associated with these risk factors involving the hospital stay of patients with myalgia. METHODS: Data were collected from hospitals around the United States through the NIS, and these data were narrowed down to those patients suffering from myalgia. These data were then analyzed using SAS Enterprise Guide 4. Data visualization techniques, logistic regression and linear models were used to achieve the desired results. RESULTS: It was determined that females are the most abundant among myalgia sufferers with a peak age around 56. The males subjects with myalgia had a broad peak of 43 to 65 years of age. This condition has occurred in most women by the age of 58. It was also determined that the Asian/Pacific Islanders demonstrated a peak age of around 70 in comparison to the average age of 58.3. Asians have the lowest probability of accumulating less than $20,000 in total charges and Caucasians, African-Americans, and Native Americans have the highest. Asians also have the highest probability among the races of accumulating between $38,000 and $58,000 in charges. Caucasians were determined to have the least probability of staying less than five days in the hospital and Asians have the highest probability of staying between 11 and 16 days. A linear model revealed that the following DX and DRG codes are significant in predicting total charges and also surround heart and blood conditions: Transfusion of packed cells, anemia (unspecified), venous catheterization (not elsewhere classified), of native coronary artery, congestive heart failure (unspecified), and atrial fibrillation. CONCLUSION: There is currently limited data on the risk factors of myalgia and these results will hopefully be a start to learning more about the condition.